ArticleBMC cancer2020

Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.

Susan A Kennedy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.